Loading...
•
Dec 31, 2019
Qualigen Q4 2019 Earnings Report
Ritter Pharmaceuticals reported financial results for Q4 2019, showing a net loss decrease due to winding down development efforts as the Liberatus clinical trial entered its finalization stage, and announced a definitive merger agreement with Qualigen, Inc.
Key Takeaways
Ritter Pharmaceuticals reported a net loss of $0.4 million for the fourth quarter ended December 31, 2019, compared to a net loss of $6.6 million for the same period in 2018. The company's cash and cash equivalents were approximately $1.7 million as of December 31, 2019. A definitive merger agreement with Qualigen, Inc. was announced in January 2020.
Net loss for Q4 2019 was $0.4 million, compared to $6.6 million for Q4 2018.
Net loss per share for Q4 2019 was $0.05, compared to $1.73 for Q4 2018.
Cash and cash equivalents were approximately $1.7 million as of December 31, 2019.
A definitive merger agreement with Qualigen, Inc. was announced in January 2020.